Regulatory Approval Milestones. Nestlé will pay the Company the following milestone payments within [**] days of the achievement of the relevant milestone event as described below: Provided, however that in the event: [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
(a) [**] of a Product does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.2 will be reduced by [**].
(b) [**] of a Product does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.2 will be reduced by [**].
(c) [**] of a Product does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.2 will be reduced by [**].
(d) [**] of a Product does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.2 will be reduced by [**]. Such deductions in clauses (a) through (d) not to be cumulatively applied.
Regulatory Approval Milestones. 4.1.1. Nestlé will pay the Company the following milestone payments within [**] days of the achievement of the relevant milestone event as described below: Provided, however that in the event:
(a) [**] does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.1 will be reduced by [**]. [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
(b) the First Regulatory Approval for [**] for Maintenance does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.1 will be reduced by [**].
(c) [**] does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.1 will be reduced by [**].
(d) [**] does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.1 will be reduced by [**].
(e) [**] does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.1 will be reduced by [**].
(f) [**] does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.1 will be reduced by [**].
(g) [**] does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.1 will be reduced by [**].
(h) [**] does not occur by [**] the relevant milestone payment for the delayed milestone event owed by Nestlé pursuant to this Section 4.1 will be reduced by [**]. Such deductions in clauses (a) through (h) not to be cumulatively applied.
Regulatory Approval Milestones. Nestlé will pay the Company the following milestone payments within [**] days of the achievement of the relevant milestone event as described below: Provided, however that in the event:
Regulatory Approval Milestones. The following payments (each, an “Approval Milestone Payment”) shall be made on a one-time basis with respect to the first Product to achieve corresponding milestone event (each, an “Approval Milestone”), if and only if the Co-Funding Term is not in effect when such Approval Milestone is achieved.
Regulatory Approval Milestones. The Regulatory Approval Milestones described above are not dependent upon the scope of the Regulatory Approval; provided, however that in the event the Regulatory Approval triggering a Regulatory Approval Milestone is subject to the satisfaction of additional requirements before Lundbeck becomes legally permitted to market and sell the Product in the country or jurisdiction in respect of which such Regulatory Approval was granted, then the Regulatory Approval Milestone shall not become payable until such requirements are satisfied, or Lundbeck is otherwise legally permitted to market and sell the Product in such country or jurisdiction, unless a new Regulatory Approval triggering the payment of such Regulatory Approval Milestone without such restrictions is granted in the interim period in another country or jurisdiction. Upon the achievement of each of the Regulatory Approval Milestones, Lundbeck may elect to terminate this Agreement in accordance with Article 12.5.1(a) by delivering written notice to Myriad on or before the date the applicable Regulatory Approval Milestone is to be paid, in which case such Regulatory Approval Milestone will not be payable by Lundbeck and this Agreement will terminate.
Regulatory Approval Milestones. Pharvaris shall make to AnalytiCon the following one-time regulatory approval milestone payments: [*****] [***** ] [*****] [***** ]
Regulatory Approval Milestones. Milestone Event (per Collaboration Target) Payment for BI Collaboration Projects Payment for Forma Collaboration Projects [***] [***] [***] [***] [***] [***] [***] [***] [***]
Regulatory Approval Milestones. Company shall pay Institution an aggregate fee of [REDACTED: Amount] in three (3) equal installments upon the first occurrence of each of the following regulatory approval milestones for the Product (each, a “Regulatory Milestone”, and each such amount, a “Regulatory Milestone Payment”):
Regulatory Approval Milestones. Affini-T shall notify to Metagenomi within [***] after the first achievement of each of the following Regulatory Approval milestone events with respect to each Affini-T Clinical Target once for each Field. Metagenomi shall submit an invoice for the applicable payment to Affini-T pursuant to Section 8.4.5(c) and Affini-T shall, within [***] of receipt of such invoice, make the following payments once for each Field, on an Affini-T Clinical Target-by-Affini-T Clinical Target basis (and corresponding to whether the Licensed Product achieving the relevant milestone is an Exclusively Licensed Product or a Non-Exclusively Licensed Product). Each Regulatory Approval milestone shall be payable only once for each Affini-T Clinical Target in each Field regardless of the number of Exclusively Licensed Products or Non-Exclusively Licensed Products associated with such Affini-T Clinical Target that achieve such milestone event. In the event a Licensed Product is directed to more than one Affini-T Clinical Target, such Licensed Product shall only trigger payment of applicable Regulatory Approval milestone amounts for a single Affini-T Clinical Target. Regulatory Approval Milestone Event in a Field Exclusively Licensed Product Milestone Payment ($ US Dollars) Non-Exclusively Licensed Product Milestone Payment ($ US Dollars) [***] [ ***] [ ***] [***] [ ***] [ ***] [***] [ ***] [ ***] Regulatory Approval Milestone Event in a Field Exclusively Licensed Product Milestone Payment ($ US Dollars) Non-Exclusively Licensed Product Milestone Payment ($ US Dollars) Maximum Total Regulatory Approval Milestone Payments $40,625,000 for each Affini-T Clinical Target if all Regulatory Approval Milestones were achieved by an Exclusively Licensed Product and a Non-Exclusively Licensed Product both directed to such Affini-T Clinical Target [***]
Regulatory Approval Milestones. Following the Effective Date and subject to Section 11.8, in partial consideration of Scynexis’s grant of the rights and licenses to GSK hereunder, GSK shall pay to Scynexis, in accordance with the terms in this Section 6.3, the following one-time, non-refundable, non-creditable milestone payments (each, a “Regulatory Approval Milestone Payment”) upon the first achievement by or on behalf of GSK or any of its Affiliates or Sublicensees of the corresponding milestone event (each, a “Regulatory Approval Milestone Event”). First NDA approval by the FDA for any Product [***] in the United States $[***] First MAA approval for any Product [***] (a) in at least [***] ([***]) of the following countries: [***] or (b) by the European Commission based on the recommendation by the EMA $[***] First JNDA approval by the PMDA for any Product [***] in Japan $[***] First NDA (or supplemental NDA) approval by the FDA for any Product [***] in the United States $[***] First NDA (or supplemental NDA) approval by the FDA for any Product [***] in the United States [***] $[***] First NDA (or supplemental NDA) approval by the FDA for any Product [***] in the United States [***] $[***] For clarity, (i) each Regulatory Approval Milestone Payment shall be paid only one time, regardless of the number of Products, the number of Indications for which a Product is Commercialized, or the number of times a given Regulatory Approval Milestone Event has been achieved, and in no event will GSK be responsible for more than an aggregate of Seventy Million Dollars ($70,000,000) in Regulatory Approval Milestone Payments and (ii) a single NDA Approval can trigger the achievement of one or more Regulatory Approval Milestone Events if the scope of such NDA Approval achieves the requirements of such Regulatory Approval Milestone Events and such Regulatory Approval Milestone Events have not been achieved prior to such NDA Approval. GSK shall notify Scynexis within [***] ([***]) following the first achievement of a given Regulatory Approval Milestone Event by GSK or any of its Affiliates or Sublicensees, and the corresponding Regulatory Approval Milestone Payment shall be due within [***] ([***]) after GSK’s receipt of a Valid Invoice in accordance with Section 6.7 for such Regulatory Approval Milestone Payment.
